{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=aflibercept+2mg&page=2",
    "query": {
      "intervention": "aflibercept 2mg",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=aflibercept+2mg&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-29T10:52:30.139Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06223958",
      "title": "Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neovascular Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "OTX-TKI (axitinib implant)",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ocular Therapeutix, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 344,
      "start_date": "2024-01-29",
      "completion_date": "2027-09-27",
      "has_results": false,
      "last_update_posted_date": "2025-04-18",
      "last_synced_at": "2026-09-29T10:52:30.139Z",
      "location_count": 97,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 81 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06223958"
    },
    {
      "nct_id": "NCT01363440",
      "title": "Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)",
          "type": "DRUG"
        },
        {
          "name": "Macular Laser Photocoagulation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 466,
      "start_date": "2011-05",
      "completion_date": "2014-11",
      "has_results": true,
      "last_update_posted_date": "2016-05-30",
      "last_synced_at": "2026-09-29T10:52:30.139Z",
      "location_count": 51,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 48 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01363440"
    },
    {
      "nct_id": "NCT04684394",
      "title": "A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neovascular Age-related Macular Degeneration",
        "Retinal Disease",
        "Retinal Degeneration",
        "Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "GEM103",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Aflibercept",
          "type": "DRUG"
        },
        {
          "name": "Sham",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Gemini Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2020-12-29",
      "completion_date": "2022-02-18",
      "has_results": true,
      "last_update_posted_date": "2022-10-31",
      "last_synced_at": "2026-09-29T10:52:30.139Z",
      "location_count": 23,
      "location_summary": "Phoenix, Arizona • Campbell, California • Encino, California + 19 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Campbell",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04684394"
    },
    {
      "nct_id": "NCT07705555",
      "title": "A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetic Retinopathy",
        "Macular Edema"
      ],
      "interventions": [
        {
          "name": "MK-8748",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 960,
      "start_date": "2026-08-27",
      "completion_date": "2029-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-28",
      "last_synced_at": "2026-09-29T10:52:30.139Z",
      "location_count": 11,
      "location_summary": "Glendale, California • Denver, Colorado • Tampa, Florida + 8 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Hagerstown",
          "state": "Maryland"
        },
        {
          "city": "Bloomfield",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07705555"
    },
    {
      "nct_id": "NCT02559180",
      "title": "Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetic Retinopathy",
        "Macular Edema"
      ],
      "interventions": [
        {
          "name": "aflibercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rishi Singh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2015-10",
      "completion_date": "2020-12",
      "has_results": true,
      "last_update_posted_date": "2023-03-30",
      "last_synced_at": "2026-09-29T10:52:30.139Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02559180"
    },
    {
      "nct_id": "NCT01868360",
      "title": "Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Corneal Neovascularization"
      ],
      "interventions": [
        {
          "name": "Subconjunctival aflibercept",
          "type": "DRUG"
        },
        {
          "name": "Placebo: Standard of care only",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Balamurali Ambati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2013-06",
      "completion_date": "2015-10",
      "has_results": false,
      "last_update_posted_date": "2015-10-07",
      "last_synced_at": "2026-09-29T10:52:30.139Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01868360"
    },
    {
      "nct_id": "NCT07501052",
      "title": "Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neovascular (Wet) Age-Related Macular Degeneration",
        "Retinal Vein Occlusion",
        "Diabetic Macular Edema",
        "Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "SCD411 0.05mL (2mg)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sam Chun Dang Pharm. Co. Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2026-05-13",
      "completion_date": "2026-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-08",
      "last_synced_at": "2026-09-29T10:52:30.139Z",
      "location_count": 4,
      "location_summary": "Stuart, Florida • Winter Haven, Florida • Lemont, Illinois + 1 more",
      "locations": [
        {
          "city": "Stuart",
          "state": "Florida"
        },
        {
          "city": "Winter Haven",
          "state": "Florida"
        },
        {
          "city": "Lemont",
          "state": "Illinois"
        },
        {
          "city": "Liverpool",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07501052"
    },
    {
      "nct_id": "NCT03531294",
      "title": "Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "Aflibercept Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Greater Houston Retina Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2018-05-23",
      "completion_date": "2021-04-09",
      "has_results": false,
      "last_update_posted_date": "2021-05-21",
      "last_synced_at": "2026-09-29T10:52:30.139Z",
      "location_count": 2,
      "location_summary": "Houston, Texas • The Woodlands, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "The Woodlands",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03531294"
    },
    {
      "nct_id": "NCT04580147",
      "title": "Intravitreal Aflibercept for the Prevention of Proliferative Vitreoretinopathy Following Retinal Detachment Repair",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Retinal Detachment With Multiple Breaks, Unspecified Eye",
        "Proliferative Vitreoretinopathy"
      ],
      "interventions": [
        {
          "name": "Intravitreal aflibercept injection",
          "type": "DRUG"
        },
        {
          "name": "Sham control",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "M. Ali Khan, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2020-10-15",
      "completion_date": "2023-12-15",
      "has_results": false,
      "last_update_posted_date": "2022-05-03",
      "last_synced_at": "2026-09-29T10:52:30.139Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04580147"
    },
    {
      "nct_id": "NCT04527107",
      "title": "A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus",
        "Diabetic Retinopathy",
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "THR-149 dose level 1",
          "type": "DRUG"
        },
        {
          "name": "THR-149 dose level 2",
          "type": "DRUG"
        },
        {
          "name": "THR-149 dose level 3",
          "type": "DRUG"
        },
        {
          "name": "THR-149 0.13mg",
          "type": "DRUG"
        },
        {
          "name": "THR-149 0.13mg + aflibercept 2mg",
          "type": "DRUG"
        },
        {
          "name": "aflibercept 2mg + THR-149 0.13mg",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept 2mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oxurion",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 135,
      "start_date": "2020-07-31",
      "completion_date": "2023-11-22",
      "has_results": false,
      "last_update_posted_date": "2023-11-27",
      "last_synced_at": "2026-09-29T10:52:30.139Z",
      "location_count": 41,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 32 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04527107"
    }
  ]
}